Lahoud John, Patel Manish I, Naher Sayeda, Mercieca-Bebber Rebecca
Specialty of Surgery, Sydney Medical School The University of Sydney Sydney NSW Australia.
Department of Urology Westmead Hospital Westmead NSW Australia.
BJUI Compass. 2024 Feb 27;5(6):524-540. doi: 10.1002/bco2.339. eCollection 2024 Jun.
To determine the functional domains and symptom scales that affect patients most following radical cystectomy (RC) and urinary diversion (UD), and if a single instrument (or combination) adequately captures these bothersome symptoms. It is unclear whether current patient reported outcome (PRO) instruments that have been used to assess quality of life in patients following RC and UD adequately cover the most bothersome symptoms affecting patients.
A systematic search of MEDLINE, EMBASE, PubMed, Cinahl and Cochrane was conducted from January 2000 to May 2023 for original articles of patients who had RC and UD since 2000 for muscle invasive bladder cancer. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) process was followed. Extracted data included the PRO measures used, domains reported and scores in the first 12 months post-surgery (short-term) and after 12 months (long-term). A conservative threshold of <70 for functional domains and >30 for symptom domains was used to determine which PRO domains were potentially concerning to patients in each study. Quality assessment was performed using the QUALSYST appraisal tool.
Thirty-five studies met the inclusion criteria, including a total of eight unique PRO instruments. The main findings indicated that physical function was the most concerning PRO for patients with both neobladder (NB) and ileal conduit (IC) in the short and long term. Additionally, bowel, urinary and sexual bother were concerning symptoms for patients with NB in the long-term, but only in the short-term for those with IC.
The main issues are adequately addressed using the combination of EORTC QLQ-C30 and QLQ-BLM30 instruments.
确定根治性膀胱切除术(RC)和尿流改道(UD)后对患者影响最大的功能领域和症状量表,以及单一工具(或组合)是否能充分捕捉这些令人烦恼的症状。目前用于评估RC和UD术后患者生活质量的患者报告结局(PRO)工具是否充分涵盖了影响患者的最令人烦恼的症状尚不清楚。
从2000年1月至2023年5月,对MEDLINE、EMBASE、PubMed、Cinahl和Cochrane进行系统检索,以查找自2000年以来因肌层浸润性膀胱癌接受RC和UD的患者的原始文章。遵循系统评价和Meta分析的首选报告项目(PRISMA)流程。提取的数据包括所使用的PRO测量方法、报告的领域以及术后前12个月(短期)和12个月后(长期)的得分。使用功能领域<70和症状领域>30的保守阈值来确定每项研究中哪些PRO领域可能与患者相关。使用QUALSYST评估工具进行质量评估。
35项研究符合纳入标准,共包括8种独特的PRO工具。主要研究结果表明,无论是短期还是长期,新膀胱(NB)和回肠导管(IC)患者最关心的PRO都是身体功能。此外,肠道、泌尿和性功能困扰是NB患者长期关注的症状,但IC患者仅在短期内关注。
使用欧洲癌症研究与治疗组织QLQ-C30和QLQ-BLM30工具的组合可以充分解决主要问题。